Anti-VEGF drugs and clinical trials

Todd R. Klesert, Jennifer I. Lim, Philip J Rosenfeld

Research output: Chapter in Book/Report/Conference proceedingChapter


In 1989, Ferrara and Henzel (1) isolated a diffusible protein from bovine pituitary follicular cells that showed cell-specific mitogenic activity for vascular endothelium. They named this protein vascular endothelial growth factor (VEGF). Further research showed that VEGF was in fact Michelson’s factor X, which was the postulated diffusible angiogenesis factor (2). As discussed in Chapter 5, VEGF was then shown to have a major role in choroidal neovascularization (CNV) (3,4).

Original languageEnglish (US)
Title of host publicationAge-Related Macular Degeneration, Second Edition
PublisherCRC Press
Number of pages10
ISBN (Electronic)9781420019865
ISBN (Print)9780849372148
StatePublished - Jan 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Anti-VEGF drugs and clinical trials'. Together they form a unique fingerprint.

Cite this